Aptevo Therapeutics (NASDAQ:APVO) Now Covered by StockNews.com

StockNews.com started coverage on shares of Aptevo Therapeutics (NASDAQ:APVO) in a research report released on Monday morning. The brokerage issued a sell rating on the biotechnology company’s stock.

Separately, Roth Mkm lowered their price target on shares of Aptevo Therapeutics from $20,535.00 to $10,952.00 and set a “buy” rating on the stock in a report on Monday, September 23rd.

Aptevo Therapeutics Stock Down 10.0 %

Shares of APVO opened at $8.73 on Monday. The stock has a 50-day moving average of $302.11 and a two-hundred day moving average of $496.00. Aptevo Therapeutics has a one year low of $5.11 and a one year high of $399.60.

Hedge Funds Weigh In On Aptevo Therapeutics

An institutional investor recently bought a new position in Aptevo Therapeutics stock. Armistice Capital LLC bought a new stake in Aptevo Therapeutics Inc. (NASDAQ:APVO) in the 2nd quarter, according to its most recent disclosure with the SEC. The fund bought 749,234 shares of the biotechnology company’s stock, valued at approximately $229,000. Armistice Capital LLC owned approximately 18.36% of Aptevo Therapeutics at the end of the most recent reporting period. Institutional investors own 8.06% of the company’s stock.

Aptevo Therapeutics Company Profile

Aptevo Therapeutics Inc, a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. It develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells.